By integrating pH-responsiveness, high drug loading, and synergistic potential with targeted therapies like trastuzumab, our system offers a rational and translational strategy for overcoming the limitations of conventional chemotherapy in refractory HER2+ breast cancer. Here, ERBB2 is linked to breast carcinoma.